EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions

Christina Kovar iD, Helena Leonie Hanae Loer, Simeon Rüdesheim iD, Laura Maria Fuhr, Fatima Zahra Marok, Dominik Selzer iD, Matthias Schwab iD, Thorsten Lehr iD

CPT: Pharmacometrics & Systems Pharmacology · 2024-07 · 13 (7) · 1144-1159

DOI: 10.1002/psp4.13146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024-05. Verfasst von Christina Kovar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy, Saarland University, Saarbrücken, Germany. Hauptthemen laut MEDLINE: Dasatinib, Drug Interactions, Cytochrome P-450 CYP3A Inhibitors, Models, Biological. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Horizon.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dasatinib, a second‐generation tyrosine kinase inhibitor, is approved for treating chronic myeloid and acute lymphoblastic leukemia. As a sensitive cytochrome P450 (CYP) 3A4 substrate and weak base with strong pH‐sensitive solubility, dasatinib is susceptible to enzyme‐mediated drug–drug interactions (DDIs) with CYP3A4 perpetrators and pH‐dependent DDIs with acid‐reducing agents. This work aimed to develop a whole‐body physiologically‐based pharmacokinetic (PBPK) model of dasatinib to describe and predict enzyme‐mediated and pH‐dependent DDIs, to evaluate the impact of strong and moderate CYP3A4 inhibitors and inducers on dasatinib exposure and to support optimized dasatinib dosing. Overall, 63 plasma profiles from perorally administered dasatinib in healthy volunteers and cancer patients were used for model development. The model accurately described and predicted plasma profiles with geometric mean fold errors (GMFEs) for area under the concentration–time curve from the first to the last timepoint of measurement (AUC last ) and maximum plasma concentration ( C max ) of 1.27 and 1.29, respectively. Regarding the DDI studies used for model development, all (8/8) predicted AUC last and C max ratios were within twofold of observed ratios. Application of the PBPK model for dose adaptations within various DDIs revealed dasatinib dose reductions of 50%–80% for strong and 0%–70% for moderate CYP3A4 inhibitors and a 2.3–3.1‐fold increase of the daily dasatinib dose for CYP3A4 inducers to match the exposure of dasatinib administered alone. The developed model can be further employed to personalize dasatinib therapy, thereby help coping with clinical challenges resulting from DDIs and patient‐related factors, such as elevated gastric pH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DasatinibDrug InteractionsCytochrome P-450 CYP3A InhibitorsModels, BiologicalProtein Kinase InhibitorsHumansCytochrome P-450 CYP3A InducersCytochrome P-450 CYP3AMaleAdultArea Under CurveFemaleAntineoplastic AgentsMiddle Aged

Substanzen

DasatinibCytochrome P-450 CYP3A InhibitorsProtein Kinase InhibitorsCytochrome P-450 CYP3A InducersCytochrome P-450 CYP3AAntineoplastic AgentsCYP3A4 protein, human

Autor:innen und Institutionen

  • Clinical Pharmacy, Saarland University, Saarbrücken, Germany.
  • Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
  • Departments of Clinical Pharmacology, and Pharmacy and Biochemistry, University of Tübingen, Tübingen, Germany.
  • Cluster of Excellence iFIT (EXC2180), Image-Guided and Functionally Instructed Tumor Therapies, University of Tübingen, Tübingen, Germany.

ORCID-Profile: Christina Kovar, Simeon Rüdesheim, Dominik Selzer, Matthias Schwab, Thorsten Lehr

Förderung

  • European Horizon

Zitieren

APA

Kovar, C., Loer, H. L. H., Rüdesheim, S., Fuhr, L. M., Marok, F. Z., Selzer, D., Schwab, M., & Lehr, T. (2024). A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions. CPT: Pharmacometrics & Systems Pharmacology, 13(7), 1144-1159. https://doi.org/10.1002/psp4.13146

Vancouver

Kovar C, Loer HLH, Rüdesheim S, Fuhr LM, Marok FZ, Selzer D, et al. A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(7):1144-1159. doi:10.1002/psp4.13146

BibTeX
@article{Kovar2024,
  author = {Kovar, Christina and Loer, Helena Leonie Hanae and Rüdesheim, Simeon and Fuhr, Laura Maria and Marok, Fatima Zahra and Selzer, Dominik and Schwab, Matthias and Lehr, Thorsten},
  title = {A physiologically‐based pharmacokinetic precision dosing approach to manage dasatinib drug–drug interactions},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2024},
  volume = {13},
  number = {7},
  pages = {1144--1159},
  doi = {10.1002/psp4.13146}
}
Kostenlos starten →